Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily shot free teens from calcium pills?

NCT ID NCT07706764

Recruiting now Disease control Sponsor: Ascendis Pharma A/S Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests a daily injection called palopegteriparatide (Yorvipath) in adolescents aged 12 to 18 with chronic hypoparathyroidism, a condition where the body cannot regulate calcium levels. The goal is to see if the drug can safely bring calcium into the normal range while allowing participants to stop taking active vitamin D and high-dose calcium supplements. The trial follows participants for 234 weeks and is being conducted in Europe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a daily injection of palopegteriparatide (also known as Yorvipath)
What this could lead to
If successful, this could offer adolescents with chronic hypoparathyroidism a way to control calcium levels without needing daily vitamin D or high-dose calcium supplements.
What could go wrong
This is a small, single-arm study with no placebo group, so results may not be definitive. Long-term safety and effectiveness beyond 234 weeks are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypoparathyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOPARATHYROIDISM

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ascendis Pharma Investigational Site

    RECRUITING

    Lodz, 93-338, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.